ArticleEuropean journal of medical research2025
Association between metformin use and reduced short- and long-term all-cause mortality in patients undergoing cardiac surgery: a retrospective cohort study.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metformin Beyond Glycemic Control: Cardiovascular Protection and Diabetes Prevention.Journal of cardiovascular development and disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimsThe use of metformin during the perioperative period remains a contentious issue. This study aimed to assess the impact of metformin use on overall mortality rates among patients in postoperative cardiac intensive care units. MATERIALS AND
methodsThis study retrospectively analyzed data from 8675 cardiac surgery patients sourced from the Medical Information Marketplace in Intensive Care (MIMIC 3.0) database. The administration of metformin during the postoperative ICU stay was assessed. Utilizing Cox proportional hazards modeling, the study explored the correlation between metformin treatment and all-cause mortality (ACM). The impact of metformin on survival rates was examined using the Kaplan-Meier method. Subgroup analyses and interaction tests were conducted to ascertain the consistency of these associations across diverse demographic and clinical subgroups.
resultsThe average age of participants in this study was 69.0 years, spanning from 61.0 to 76.0 years. A higher proportion of individuals who received metformin following surgery were male (75.6% vs 72.3%, P = 0.01), younger (67.19 ± 9.26 vs 67.95 ± 11.75, P = 0.006), and had lower Sequential Organ Failure Assessment Scores (4.92 ± 2.38 vs 5.31 ± 2.79, P < 0.001). When compared with patients who did not receive metformin after surgery, these individuals who received metformin following surgery had a lower prevalence of chronic kidney disease, congestive heart failure, and peripheral vascular disease and the higher prevalence of acute myocardial infarction, hypertension and diabetes. The metformin administration was correlated to decreased ACM at 28, 60, 90, and 365 days.
conclusionsUtilizing metformin in the intensive care unit following surgery was correlated with the notable reduction in ACM among patients who have undergone cardiac procedures, particularly those with diabetes. However, further prospective research is necessary to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.